Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yuan Yang
Observed name:
Yang Yuan
Institutions:
First Affiliated Hospital of University of South China,
University of South China
Observed institutions:
Shenyang Pharmaceutical University,
First Affiliated Hospital of University of South China,
University of South China
ORCID:
0009-0002-9313-3074
Observed ORCID:
0009-0002-9313-3074
OpenAlex ID:
A5100576750
PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy
2024
·
Simeng Wang
, Dongliang Su
, et al.
·
Cell Death and Differentiation
·
15
PDF
The promoting effect of the POU3F2/METTL16/PFKM cascade on glycolysis and tumorigenesis of hepatocellular carcinoma
2025
·
Ming Chen
, Yuan Yang
, et al.
·
Annals of Hepatology
·
11
Advanced anaplastic thyroid carcinoma with positive expression of PD-L1 response to immune checkpoint inhibitors: A case report
2025
·
Shanmin Fan
, Yang Yuan
, et al.
·
SAGE Open Medical Case Reports
·
6
Loss of AXIN1 regulates response to lenvatinib through a WNT/KDM5B/p15 signalling axis in hepatocellular carcinoma
2024
·
Chengfang Tang
, Chu Tang
, et al.
·
British Journal of Pharmacology
·
4
PDF
WTX212, an erythrocyte-anti-PD1 antibody conjugate, to demonstrate anti-tumor activities in tumor models and patients with cancer with acquired resistance to immunotherapy.
2023
·
Nie Xiaoqian
, Yuehua Liu
, et al.
·
Journal of Clinical Oncology
·
4
PDF
International Experiences and Global Competence of Chinese Graduate Students Amid the COVID-19 Pandemic
2023
·
Yuhao Cen
, Yuan Yang
·
Journal of college student development
·
1
The role of WTX212, an erythrocyte-anti-PD1 antibody conjugate, in anti-tumor activities in tumor models and cancer patients with acquired resistance to immunotherapy.
2023
·
Xiaoqian Nie
, Yuehua Liu
, et al.
·
JCO Global Oncology
PDF
Show more works
View as search
Works count:
7
Citation count:
41
H-index:
4
I10-index:
2
Year
Topic
Type